Clinical Results | Apr 20, 2018
Clinical Results

Symic reports Phase I/II data for SB-030 in peripheral vascular disease

Symic Bio Inc. (Emeryville, Calif.) reported data from the single-blind, Australian and New Zealand Phase I/II SHIELD trial in 67 patients with symptomatic peripheral vascular disease undergoing angioplasty showing that SB-030 (SBVC) significantly reduced index...
BC Extra | May 23, 2017
Financial News

Symic Bio raises $30M in series B

Matrix biology company Symic Bio Inc. (Emeryville, Calif.) raised $30 million in a series B round from new investor HEDA Ventures and existing investors Lilly Ventures, Den Danske Forskningsfond, Ally Bridge Group, InCube Ventures and...
BioCentury | Aug 15, 2016
Finance

Serving returns

China's Ally Bridge Group hit the investment world's radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that...
BC Innovations | Apr 7, 2016
Product R&D

Branching out

With its second compound about to hit the clinic and a fresh influx of money, Symic Biomedical Inc. is lining up the next three preclinical programs for its extracellular matrix (ECM)-targeting technology. By applying each...
BC Extra | Dec 2, 2015
Financial News

Symic raises $25M in series A-2 round

Symic Biomedical Inc. (San Francisco, Calif.) raised $25 million in a series A-2 round led by existing investor Lilly Ventures. New investors Alexandria Real Estate and Purdue Research Foundation also participated, as did existing investors...
BC Week In Review | Nov 9, 2015
Clinical News

SB-030: Phase I/II started

Symic began the double-blind, placebo-controlled, international Phase I/II SHIELD trial to evaluate balloon angioplasty with or without single doses of locally applied SB-030 in about 66 patients undergoing procedures for stenosis or occlusion within the...
BioCentury | Jan 5, 2015
Emerging Company Profile

Mimicking proteoglycans

Symic Biomedical Inc. is developing a library of synthetic mimics that function like natural proteoglycans but are easier to manufacture and aren't susceptible to enzymatic degradation, opening up previously untapped therapeutic space. Proteoglycans, which are...
BC Week In Review | Feb 22, 2000
Clinical News

ImuLyme: Discontinued Development

Aventis Pasteur Inc., Swiftwater, Penn.   Product: ImuLyme   Business: Infectious diseases   Therapeutic category: Immune stimulation, Bacterial infection   Target: Immune cells   Description: Recombinant outer-surface protein A (OspA) of Borrelia burgdorferi   Indication:...
BC Week In Review | Jul 12, 1999
Clinical News

MedImmune Inc. preclinical data

In mice, a combination vaccine developed by MEDI and partner Pasteur Merieux Connaught prevented infection at all challenge doses of Borrelia burgdorferi bacteria. Low doses of the combination vaccine were more effective than higher doses...
BC Week In Review | Dec 7, 1998
Company News

MedImmune Inc., Pasteur Merieux deal

Pasteur Merieux, a subsidiary of Rhone-Poulenc S.A. (Paris, France), received exclusive worldwide rights to MEDI's decorin binding protein, which is found on organisms that cause Lyme disease, to develop a second-generation vaccine. MEDI is eligible...
Items per page:
1 - 10 of 15